A Phase 1, Open Label, Fixed-sequence Study to Evaluate the Effect of BAY1841788 (ODM-201) on Drug Transporters Using Rosuvastatin as Probe Substrate and to Assess Pharmacokinetics and Safety of BAY1841788 in Female and Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2016
At a glance
- Drugs Darolutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 07 Sep 2016 Status changed from active, no longer recruiting to completed.
- 16 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
- 16 May 2016 Status changed from recruiting to active, no longer recruiting.